The Lucira COVID-19 & Flu Home Test, the first over-the-counter (OTC) at-home diagnostic test that can detect and differentiate between SARS-CoV-2 and influenza viruses in individuals 2 years of age and older, is now available in the US. The test was granted Emergency Use Authorization by the Food and Drug Administration earlier this year.
The single-use, nucleic acid amplification test is intended for individuals with signs and symptoms consistent with a respiratory tract infection, including COVID-19. The test works by swabbing the nasal cavity and swirling the sample in a vial, which is then placed in a test unit.
Results are displayed in the test unit within 30 minutes and determine whether an individual is positive or negative for: Influenza A, Influenza B, and COVID-19. The performance of the Lucira COVID-19 & Flu Home Test was found to be comparable to lab-based PCR tests.
“US consumers will, for the first time ever, be able to diagnose if they have COVID-19 or Flu A or B while at home,” said Erik Engelson, President and CEO of Lucira Health. “With one-touch access to telehealth via our Lucira Connect web platform, they can now get onto the path to treatment and recovery within hours of receiving a test result from the comfort of home.”
The Lucira COVID-19 & Flu Home Test is available at a price of $34.99 at lucirahealth.com.
Lucira Health announces US launch of first & only at-home combination COVID-19 & Flu test amidst sale process. News release. Company. Accessed March 28, 2023. https://www.globenewswire.com/news-release/2023/03/28/2635636/0/en/Lucira-Health-Announces-U-S-Launch-of-First-Only-At-Home-Combination-COVID-19-Flu-Test-Amidst-Sale-Process.html